Daxxify vs. Xeomin: Peptide-Stabilized Long-Acting Toxin vs. the “Naked Toxin” (2026 Guide)

If you are weighing Daxxify against Xeomin, you are comparing the two cosmetic neurotoxins that take the most distinctive approaches to formulation. Both are FDA-approved type A botulinum toxins. But each strips out a different piece of the conventional Botox formulation — Xeomin removes the accessory complexing proteins to create a “naked toxin,” and Daxxify removes human serum albumin in favor of a stabilizing peptide called RTP-004.

Patients usually find their way to this comparison for one of two reasons: they want the longest possible duration (Daxxify), or they want the cleanest possible excipient profile (Xeomin). This guide walks through mechanism, onset, duration, dosing, cost, side effects, and ideal candidate for each — and because Naya does not currently carry Xeomin, we are transparent about the closest analog on our menu if Xeomin drew you in.

What Daxxify and Xeomin Actually Are

Both are purified type A botulinum toxins that temporarily block acetylcholine release at the neuromuscular junction. The differences sit in what surrounds the 150 kDa core toxin.

• Daxxify (daxibotulinumtoxinA-lanm) — Revance Therapeutics, FDA-approved for glabellar lines in September 2022. A 150 kDa core stabilized by a proprietary peptide called RTP-004 instead of human serum albumin. The peptide is the structural reason Daxxify is studied with a six-month median duration.
• Xeomin (incobotulinumtoxinA) — Merz Aesthetics, FDA-approved for glabellar lines in 2011. The “naked toxin”: a 150 kDa core with no accessory complexing proteins. The active component contains no albumin either.

The simplest framing: both start with the same 150 kDa active toxin, but take opposite approaches to what they wrap around it. Xeomin wraps nothing — that is the pitch. Daxxify wraps it in a peptide engineered to extend duration.

Onset: How Quickly Will You See Results?

This is one area where the products differ more than you might expect.

• Daxxify onset: Most patients see softening at 1–4 days, with peak effect at approximately 14 days.
• Xeomin onset: Most patients see softening at 5–7 days, with peak effect at approximately 14 days.

Xeomin’s slightly slower onset has been documented in head-to-head comparisons against Botox and is something to plan around if you have a time-sensitive event. Daxxify lands earlier for most patients and is a more flexible pick when timing matters.

Duration: Where Daxxify Pulls Away

This is the headline difference.

• Daxxify: The SAKURA program reported a median duration of approximately six months at the 40-unit glabellar dose, with a meaningful subset of patients reporting visible softening at nine months. The FDA label reflects this six-month positioning; Daxxify is currently the only cosmetic neurotoxin in the U.S. labeled this long.
• Xeomin: Studied and labeled at the standard 3 to 4 months for glabellar lines, in line with Botox, Dysport, Letybo, and Jeuveau.

On Daxxify a typical patient is in twice a year; on Xeomin, three to four times a year. That calendar difference is often the deciding factor.

Dosing and Unit Conversion

Per the FDA labels:

• Daxxify for glabellar lines: 40 units total, divided across 5 injection sites (8 units each).
• Xeomin for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).

Xeomin uses the familiar 1:1 conversion relative to Botox — an injector who is fluent in Botox dosing is fluent in Xeomin dosing. Daxxify uses a roughly 2:1 ratio relative to Botox; the unit numbers are larger because the units are defined differently, not because the muscle relaxation is stronger. A 40-unit Daxxify treatment is doing the clinical equivalent of a 20-unit Botox or Xeomin treatment, with the peptide stabilization extending how long that effect lasts.

The unit numbers between Daxxify and Xeomin are not comparable. Always compare on per-treatment-area cost, not per-unit cost.

Diffusion and Precision

Both products have tight, precise diffusion profiles when correctly placed. Xeomin’s 150 kDa naked toxin is well-controlled in the glabellar complex and has the same precision reputation as Botox; Daxxify, despite being built on the same 150 kDa core, has shown similarly tight spread thanks to peptide-mediated stabilization. Neither carries the broader diffusion footprint of Dysport. Both are appropriate for focal targets like the glabella, crow’s feet, lip lines, and bunny lines in experienced hands.

Cost: What You Will Actually Pay in 2026

The two products sit in different price brackets per treatment, and the comparison only makes sense on a per-treatment-area basis given the different unit definitions.

• Daxxify: roughly $14–$20 per unit. A standard glabellar treatment (40 units) lands around $560–$800.
• Xeomin: roughly $10–$15 per unit. A standard glabellar treatment (20 units) lands around $200–$300.

On an annualized basis, two Daxxify treatments at $700 is about $1,400; on a 3.5-month Xeomin cycle, roughly 3.4 treatments at $250 is about $850. Xeomin is cheaper annually, but Daxxify cuts clinic visits roughly in half. On per-month math the gap narrows — about $117 on Daxxify vs. about $71 on Xeomin.

Side Effects and Safety

Both products have side effect profiles consistent with the rest of the cosmetic toxin class. In FDA-controlled trials, the most common adverse events for both were:

• Headache (3–9%)
• Injection-site reactions — bruising, redness, mild swelling (1–5%)
• Eyelid heaviness or ptosis, typically less than 2% in trained hands
• Brow asymmetry, usually correctable with a small touch-up at the 2-week mark

Both carry the FDA boxed warning about the theoretical possibility of distant toxin spread; in cosmetic facial doses this has not been a meaningful clinical concern.

The excipient and antibody discussion is genuinely interesting here. Xeomin’s argument is that removing the accessory complexing proteins removes the most likely antigens, lowering the theoretical chance of neutralizing antibodies over years of repeat treatment. The clinical evidence in cosmetic doses is modest — antibody formation is rare across all products at facial doses. Daxxify takes a different angle by removing human serum albumin in favor of a synthetic peptide. If you want to avoid human-derived excipients, Daxxify is the only of the two that delivers that. If you want the fewest accessory proteins, Xeomin is the cleaner pick.

Who Is the Ideal Candidate for Each?

Daxxify may be the better fit if:

• You want to come in twice a year instead of three or four times
• You specifically want to avoid human serum albumin
• Your duration on shorter-acting toxins has consistently fallen short of 3 months
• You want the fastest onset of the two — 1 to 4 days vs. 5 to 7 days

Xeomin may be the better fit if:

• You want the cleanest possible toxin formulation in terms of accessory proteins
• You are concerned about long-term antibody formation across decades of treatment
• You prefer the familiar 1:1 Botox-style 20-unit glabellar dose
• You are price-sensitive and content with a 3 to 4 month maintenance cycle

Can You Switch Between Daxxify and Xeomin?

Yes. There is no medical reason you cannot alternate between products. A few practical notes:

• Always tell your new injector which product you previously had, the dose, and when. Daxxify’s six-month tail can still be partially active when a Xeomin top-up is considered.
• You cannot “stack” the two in the same area in the same session.
• Switching does not eliminate the small theoretical risk of antibody formation, though both products have reassuringly low immunogenicity in their clinical programs.
• If you have been on Daxxify and want to try Xeomin, wait until your prior treatment is clearly softening before re-dosing — treating into an active Daxxify effect can overshoot.